Viagra goes up AGAIN image

Daily Mail, July 2, 2018
By Mia De Graaf, quoting Rachel Sachs (Academic Fellow Alumna)

Links

Read the full article

From the article:

Economists are now calling on the Department of Health and Human Services to clarify what kind of measures they were planning on levying against companies that did not stick to the plan. 

'July 1 is a very normal time to see companies increase their drug prices,' Rachel Sachs, an associate professor of law at Washington University in St Louis with an expertise in drug pricing and patent law, told DailyMail.com.

'To see Pfizer raise the price of 100 drugs, several by 10 percent, suggests that things are very much business as usual for many large pharmaceutical companies; that the administration's rhetoric is not having an effect on their business process.'

Sachs added: 'I would be very interested to see a comment from the HHS on how they view Pfizer's move and whether they plan to move forward any regulations they say they have been planning.'

Read more here!

fda health law policy pharmaceuticals rachel sachs